Q1 EPS Estimates for Beta Bionics Cut by Leerink Partnrs

Beta Bionics, Inc. (NASDAQ:BBNX) – Equities research analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for shares of Beta Bionics in a report released on Wednesday, March 26th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings of ($0.51) per share for the quarter, down from their prior forecast of ($0.50). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Beta Bionics’ Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.83) EPS and FY2027 earnings at ($2.27) EPS.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Tuesday, March 25th. The company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($1.40). The firm had revenue of $20.44 million for the quarter, compared to analysts’ expectations of $20.01 million.

BBNX has been the topic of a number of other research reports. LADENBURG THALM/SH SH assumed coverage on shares of Beta Bionics in a report on Thursday, February 20th. They set a “neutral” rating and a $20.00 target price on the stock. Baird R W upgraded Beta Bionics to a “hold” rating in a research report on Thursday, February 20th. Robert W. Baird assumed coverage on Beta Bionics in a research report on Thursday, February 20th. They set a “neutral” rating and a $20.00 target price for the company. Bank of America assumed coverage on shares of Beta Bionics in a report on Monday, February 24th. They issued a “buy” rating on the stock. Finally, Piper Sandler started coverage on Beta Bionics in a report on Monday, February 24th. They issued an “overweight” rating and a $26.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.83.

Beta Bionics Price Performance

Shares of BBNX opened at $12.67 on Friday. Beta Bionics has a 52-week low of $12.11 and a 52-week high of $24.50.

Insider Activity

In related news, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the acquisition, the insider now directly owns 3,901,599 shares in the company, valued at approximately $66,327,183. The trade was a 34.46 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mike Mensinger bought 33,350 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were bought at an average cost of $17.00 per share, for a total transaction of $566,950.00. Following the purchase, the insider now directly owns 59,019 shares in the company, valued at approximately $1,003,323. This represents a 129.92 % increase in their position. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.